Sell Cipla, target Rs 455: Jayesh Bhanushali

Cipla Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 11968.44 Crore to Sales Value (96.72 % of Total Sales), Other Operating Revenue which contributed Rs 167.72 Crore to Sales Value (1.35 % of Total Sales), Export Incentives which contributed Rs 155.27 Crore to Sales Value (1.25 % of Total Sales), Royalty Income which contributed Rs 50.68 Crore to Sales Value (0.40 % of Total Sales) and Scrap which contributed Rs 31.90 Crore to Sales Value (0.25 % of Total Sales) for the year ending 31-Mar-2019.

For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 3894.46 Crore, down -8.82 % from last quarter Sales of Rs 4271.00 Crore and up 1.26 % from last year same quarter Sales of Rs 3845.84 Crore Company has reported net profit after tax of Rs 470.65 Crore in latest quarter. The company?s top management includes Dr.Peter Mugyenyi, Dr.Y K Hamied, Mr.Adil Zainulbhai, Mr.Ashok Sinha, Mr.M K Hamied, Mr.Peter Lankau, Mr.S Radhakrishnan, Mr.Umang Vohra, Ms.Naina Lal Kidwai, Ms.Punita Lal, Ms.Samina Vaziralli. Company has Walker Chandiok & Co. LLP as its auditors. As on 30-06-2019, the company has a total of 805,828,425 shares outstanding.